Physician profile
Alan N Bybee
NPI 1033184940
$1,026.86
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $387 · 2022: $501 · 2023: $55.34 · 2024: $83.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $83.92 · Food and Beverage: $55.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $83.92 |
| Food and Beverage | $55.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $350.01 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $260.64 | 2021-2023 | Synjardy, Jardiance |
| Medicure Pharma INC. | $83.92 | 2024 | Zypitamag |
| Pfizer INC. | $74.99 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $52.09 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $46.95 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $34.16 | 2021 | |
| Lilly USA, LLC | $26.86 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $23.79 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $18.40 | 2021 | |
| Indivior INC. | $16.26 | 2023 | Sublocade |
| Glaxosmithkline, LLC. | $14.02 | 2022 | |
| Arbor Pharmaceuticals, INC. | $12.93 | 2021 | |
| Eisai INC. | $11.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Bybee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.